A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Cho Pharma Inc.
Genmab
Novartis
CellCentric Ltd.
Incyte Corporation
Acerta Pharma BV
Genmab
Celgene
Celgene
Celgene
TG Therapeutics, Inc.
TG Therapeutics, Inc.
Merck Sharp & Dohme LLC
Celgene
Celgene
Celgene
Celgene
Celgene
Celgene
Celgene